Positive News SentimentPositive NewsNASDAQ:PRLD Prelude Therapeutics (PRLD) Stock Price, News & Analysis $5.79 -0.20 (-3.34%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$5.70▼$6.0050-Day Range$3.32▼$6.2152-Week Range$1.66▼$6.72Volume36,159 shsAverage Volume74,163 shsMarket Capitalization$243.64 millionP/E RatioN/ADividend YieldN/APrice Target$4.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Prelude Therapeutics alerts: Email Address Prelude Therapeutics MarketRank™ Stock AnalysisAnalyst RatingSell1.33 Rating ScoreUpside/Downside18.0% Downside$4.75 Price TargetShort InterestHealthy2.51% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.89Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.84) to ($1.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.63 out of 5 starsMedical Sector891st out of 936 stocksPharmaceutical Preparations Industry419th out of 436 stocks 0.7 Analyst's Opinion Consensus RatingPrelude Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.33, and is based on no buy ratings, 1 hold rating, and 2 sell ratings.Amount of Analyst CoveragePrelude Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Prelude Therapeutics' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.51% of the float of Prelude Therapeutics has been sold short.Short Interest Ratio / Days to CoverPrelude Therapeutics has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Prelude Therapeutics has recently decreased by 5.63%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPrelude Therapeutics does not currently pay a dividend.Dividend GrowthPrelude Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRLD. Previous Next 3.3 News and Social Media Coverage News SentimentPrelude Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Prelude Therapeutics this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Prelude Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Prelude Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders62.80% of the stock of Prelude Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.72% of the stock of Prelude Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Prelude Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Prelude Therapeutics are expected to decrease in the coming year, from ($1.84) to ($1.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prelude Therapeutics is -3.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prelude Therapeutics is -3.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrelude Therapeutics has a P/B Ratio of 1.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Prelude Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. About Prelude Therapeutics Stock (NASDAQ:PRLD)Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.Read More PRLD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRLD Stock News HeadlinesJuly 26 at 5:30 PM | finance.yahoo.comWe're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn RateJuly 9, 2024 | globenewswire.comPrelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated CancersJuly 26, 2024 | Behind the Markets (Ad)Rare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors.June 3, 2024 | globenewswire.comPrelude Therapeutics to Participate in Upcoming Healthcare ConferencesMay 11, 2024 | msn.comPrelude Therapeutics to Showcase at Citizens JMP Life Sciences ConferenceMay 10, 2024 | msn.comPrelude Therapeutics Progresses in Cutting-Edge Cancer Treatment DevelopmentMay 9, 2024 | globenewswire.comPrelude Therapeutics to Participate in Citizens JMP Life Sciences ConferenceMay 8, 2024 | finanznachrichten.dePrelude Therapeutics, Inc.: Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateJuly 26, 2024 | Behind the Markets (Ad)Rare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors.May 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Prelude Therapeutics on Strong Financials and Promising Clinical ProspectsMay 7, 2024 | investorplace.comPRLD Stock Earnings: Prelude Therapeutics Beats EPS for Q1 2024May 7, 2024 | globenewswire.comPrelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 13, 2024 | finance.yahoo.comSeveral Insiders Invested In Prelude Therapeutics Flagging Positive NewsApril 9, 2024 | globenewswire.comPrelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual MeetingMarch 30, 2024 | morningstar.comPrelude Therapeutics Inc Ordinary Shares PRLDMarch 16, 2024 | finance.yahoo.comPRLD Apr 2024 5.000 callMarch 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Clearside Biomedical (CLSD) and Prelude Therapeutics (PRLD)March 5, 2024 | globenewswire.comPrelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual MeetingSee More Headlines Receive PRLD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prelude Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PRLD CUSIPN/A CIK1678660 Webwww.preludetx.com Phone302-467-1280FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Stock Price Target$4.75 High Stock Price Target$7.00 Low Stock Price Target$3.00 Potential Upside/Downside-20.2%Consensus RatingSell Rating Score (0-4)1.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-121,830,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-52.97% Return on Assets-47.20% Debt Debt-to-Equity RatioN/A Current Ratio11.64 Quick Ratio11.64 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.32 per share Price / Book1.38Miscellaneous Outstanding Shares42,080,000Free Float15,653,000Market Cap$250.38 million OptionableOptionable Beta1.55 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Krishna Vaddi D.V.M. (Age 58)Ph.D., Founder, CEO & Director Comp: $905.92kDr. Edna Huang M.D. (Age 51)President & Chief Medical Officer Comp: $865.63kMr. Bryant David Lim J.D. (Age 53)Interim CFO, Chief Legal Officer & Corporate Secretary Comp: $586.42kMs. Aimee Crombie Ph.D.Senior VP and Head of Strategic Planning & OperationsDr. Madhu Pudipeddi Ph.D.Senior Vice President of Technical OperationsDr. Peggy A. Scherle Ph.D. (Age 62)Chief Scientific Officer Comp: $868.62kLindsey TrickettVice President of Investor RelationsMs. Michele Porreca M.B.A.Chief People OfficerDr. Andrew P. Combs Ph.D. (Age 57)Executive VP & Chief Chemistry Officer Comp: $562.46kMr. Naveen Babbar Ph.D.Senior Vice President of Translation MedicineMore ExecutivesKey CompetitorsZentalis PharmaceuticalsNASDAQ:ZNTLBicycle TherapeuticsNASDAQ:BCYCAnaptysBioNASDAQ:ANABCentessa PharmaceuticalsNASDAQ:CNTACronos GroupNASDAQ:CRONView All CompetitorsInstitutional OwnershipBank of New York Mellon CorpSold 3,792 shares on 7/26/2024Ownership: 0.086%Kennedy Capital Management LLCBought 25,035 shares on 5/16/2024Ownership: 0.059%Price T Rowe Associates Inc. MDSold 100,766 shares on 5/15/2024Ownership: 2.239%Vanguard Group Inc.Bought 10,143 shares on 5/10/2024Ownership: 2.417%Acadian Asset Management LLCBought 6,615 shares on 5/10/2024Ownership: 0.053%View All Institutional Transactions PRLD Stock Analysis - Frequently Asked Questions How have PRLD shares performed this year? Prelude Therapeutics' stock was trading at $4.27 at the beginning of the year. Since then, PRLD stock has increased by 35.6% and is now trading at $5.79. View the best growth stocks for 2024 here. How were Prelude Therapeutics' earnings last quarter? Prelude Therapeutics Incorporated (NASDAQ:PRLD) announced its quarterly earnings data on Tuesday, May, 7th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.47) by $0.05. When did Prelude Therapeutics IPO? Prelude Therapeutics (PRLD) raised $149 million in an initial public offering on Friday, September 25th 2020. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, Goldman Sachs and BofA Securities served as the underwriters for the IPO. Who are Prelude Therapeutics' major shareholders? Prelude Therapeutics' top institutional investors include Bank of New York Mellon Corp (0.09%). Insiders that own company stock include Orbimed Advisors Llc, Krishna Vaddi, Laurent Chardonnet, Christopher Pierce, Brian Piper, Andrew Combs, Deborah Morosini, Peggy Scherle and David J Mauro. View institutional ownership trends. How do I buy shares of Prelude Therapeutics? Shares of PRLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PRLD) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prelude Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Prelude Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRLD Stock Alerts